Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

The Investment Committee give you their top stocks to watch for the second half.

Fintel reports that on January 22, 2026, RBC Capital upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sector Perform to Outperform. Analyst Price Forecast Suggests 8.58% Upside ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its ...

The "Genetic Engineering Tool Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been ...

According to TipRanks.com, Schock is a 2-star analyst with an average return of 2.9% and a 53.3% success rate. Schock covers the Healthcare sector, focusing on stocks such as InfuSystem Holdings, ...

Explore scalable strategies for iPSC-derived islet differentiation using GMP-grade activin A and KGF to advance diabetes ...

Brian Abrahams of RBC Capital initiated an “Outperform” rating for Vertex Pharmaceuticals Incorporated (VRTX), paving the way for potential upside for investors. With a current price of $461.14 and a ...

With many more expensive gene therapies on the horizon, the cost of the sickle cell therapies presages financial challenges ...

The government is using sickle cell treatments to test a new strategy: paying only if the therapies benefit patients.

NEW YORK – Boston Children's Hospital has granted a worldwide license for an investigational gene therapy for sickle cell disease and beta thalassemia to Caring Cross, the nonprofit announced this ...

The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be ...